+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PTC Therapeutics - logo

PTC Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product candidate is Translarna (ataluren), which is for the treatment of of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is currently in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

From
From
Leigh Syndrome Treatment - Global Strategic Business Report - Product Thumbnail Image

Leigh Syndrome Treatment - Global Strategic Business Report

  • Report
  • July 2025
  • 477 Pages
  • Global
From
Dravet Syndrome - Global Strategic Business Report - Product Thumbnail Image

Dravet Syndrome - Global Strategic Business Report

  • Report
  • July 2025
  • 485 Pages
  • Global
From
Dravet Syndrome Treatment Market 2025-2029 - Product Thumbnail Image

Dravet Syndrome Treatment Market 2025-2029

  • Report
  • May 2025
  • 222 Pages
  • Global
From
From
From
From
From
From
From
Huntington's Disease Treatment Market Forecasts from 2023 to 2028 - Product Thumbnail Image

Huntington's Disease Treatment Market Forecasts from 2023 to 2028

  • Report
  • November 2023
  • 145 Pages
  • Global
From
Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Loading Indicator